Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

NCT04203901 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic corporate decision

Conditions

Advanced Renal Cell Carcinoma

Interventions

BIOLOGICAL: CMN-001
BIOLOGICAL: Nivolumab+Ipilimumab
DRUG: Lenvatinib+Everolimus

Sponsor

CoImmune